Reversal of Cushing's syndrome by vandetanib in medullary thyroid carcinoma.
Camille
C
Baudry
Anne-Cécile
AC
Paepegaey
Lionel
L
Groussin
D000324:Adrenocorticotropic Hormone / Q000097:blood; D002116:Calcitonin / Q000097:blood; D018278:Carcinoma, Neuroendocrine; D003480:Cushing Syndrome / Q000188:drug therapy* / Q000209:etiology; D003894:Deamino Arginine Vasopressin; D006801:Humans; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D010257:Paraneoplastic Syndromes / Q000188:drug therapy*; D010880:Piperidines / Q000627:therapeutic use*; D011799:Quinazolines / Q000627:therapeutic use*; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors*; D013964:Thyroid Neoplasms / Q000150:complications / Q000188:drug therapy*
D010880:Piperidines; D011799:Quinazolines; D000324:Adrenocorticotropic Hormone; D002116:Calcitonin; D040262:Receptors, Vascular Endothelial Growth Factor; D003894:Deamino Arginine Vasopressin; C452423:vandetanib